Webdisclosure.com

SANOFI-AVENTIS (EPA:SAN)

04/11/2022 08:00

Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

13/10/2022 21:58

Sanofi: Information concerning the total number of voting rights and shares - September 2022

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

29/09/2022 00:05

Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

13/09/2022 21:24

Sanofi: Information concerning the total number of voting rights and shares - August 2022

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

31/08/2022 20:30

Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

17/08/2022 07:30

Press Release: Sanofi provides update on amcenestrant clinical development program

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

08/08/2022 21:03

Sanofi: Information concerning the total number of voting rights and shares – July 2022

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

28/07/2022 14:29

Press Release: Online availability of Sanofi’s half-year financial report for 2022

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

20/07/2022 18:52

Sanofi: Information concerning the total number of voting rights and shares – June 2022

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

14/07/2022 07:00

Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

Voir tous les communiqués de SANOFI-AVENTIS

«
1
2
3
4
5
6
7
8
9
10